Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7800)
All Articles published online
|
Publishing Process of This Article
|
May 18, 2015 (publication date) through Feb 14, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Koumbi L. Current and future antiviral drug therapies of hepatitis B chronic infection. World J Hepatol 2015; 7(8): 1030-1040 [PMID: PMC4450180 DOI: 10.4254/wjh.v7.i8.1030] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v7/i8/1030.htm |
| Number | Citing Articles |
| 1 |
Soheil Tavakolpour, Hajar Sadat Mirsafaei, Somayeh Elkaei Behjati, Mojtaba Ghasemiadl, Meisam Akhlaghdoust, Shahnaz Sali. Toward cure chronic hepatitis B infection and hepatocellular carcinoma prevention: Lessons learned from nucleos(t)ide analogues therapy. Immunology Letters 2017; 190: 206 doi: 10.1016/j.imlet.2017.08.003
|
| 2 |
Sina Feustel, Fabiola Ayón-Pérez, Ana Sandoval-Rodriguez, Roberto Rodríguez-Echevarría, Homero Contreras-Salinas, Juan Armendáriz-Borunda, L. V. Sánchez-Orozco. Protective Effects of Moringa oleifera on HBV Genotypes C and H Transiently Transfected Huh7 Cells. Journal of Immunology Research 2017; 2017: 1 doi: 10.1155/2017/6063850
|
| 3 |
Ying Wang, Bairong Shen. Translational Informatics. Advances in Experimental Medicine and Biology 2022; 1368: 21 doi: 10.1007/978-981-16-8969-7_2
|
| 4 |
Yachao Tao, Dongbo Wu, Lingyun Zhou, Enqiang Chen, Changhai Liu, Xiaoqiong Tang, Wei Jiang, Ning Han, Hong Li, Hong Tang. Hepatitis B Virus Infection. Advances in Experimental Medicine and Biology 2020; 1179: 137 doi: 10.1007/978-981-13-9151-4_6
|
| 5 |
Mia Cahill, Chris Ontiveros. The Liver Meeting 2016. EMJ Hepatology 2017; : 2 doi: 10.33590/emjhepatol/10312166
|
| 6 |
Cheng Peng, Mengji Lu, Dongliang Yang. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV. Virologica Sinica 2015; 30(5): 317 doi: 10.1007/s12250-015-3660-x
|
| 7 |
Lukasz T. Olenginski, Solomon K. Attionu, Erica N. Henninger, Regan M. LeBlanc, Andrew P. Longhini, Theodore K. Dayie. Hepatitis B Virus Epsilon (ε) RNA Element: Dynamic Regulator of Viral Replication and Attractive Therapeutic Target. Viruses 2023; 15(9): 1913 doi: 10.3390/v15091913
|
| 8 |
Iao-Fai Lam, Min Huang, Margaret Dah-Tysr Chang, Pei-Wun Yao, Yu-Ting Chou, Sim-Kun Ng, Ying-Lin Tsai, Yu-Chang Lin, Yun-feng Zhang, Xiao-yuan Yang, Yiu-Kay Lai. Identification of anti-HBV activities in Paeonia suffruticosa Andr. using GRP78 as a drug target on Herbochip®. Chinese Medicine 2017; 12(1) doi: 10.1186/s13020-017-0132-2
|
| 9 |
KASL clinical practice guidelines for management of chronic hepatitis B. Clinical and Molecular Hepatology 2019; 25(2): 93 doi: 10.3350/cmh.2019.1002
|
| 10 |
Zhihao Zhang, Ping He, Yan Zhou, Xuhua Xie, Shuying Feng, Changyu Sun. Anti‑HBV effect of interferon‑thymosin α1 recombinant proteins in transgenic Dunaliella�salina in�vitro and in�vivo. Experimental and Therapeutic Medicine 2018; doi: 10.3892/etm.2018.6227
|
| 11 |
Xieer Liang, Rong Fan, Jian Sun, Javed Shaikh, Ankush Taneja, Subhajit Gupta, Kamal Hamed. Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis. Advances in Therapy 2016; 33(4): 519 doi: 10.1007/s12325-016-0305-x
|
| 12 |
Mohammed Ageeli Hakami, Farhan R. Khan, Osama Abdulaziz, Khalid Alshaghdali, Ali Hazazi, Awad F. Aleissi, Adil Abalkhail, Bader S. Alotaibi, Abdulfattah Yahya M. Alhazmi, Neelima Kukreti, Abdulkarim S. Binshaya. Varicella‐zoster virus‐related neurological complications: From infection to immunomodulatory therapies. Reviews in Medical Virology 2024; 34(4) doi: 10.1002/rmv.2554
|
| 13 |
Fatima Akram, Hafiza Marium Waheed, Fatima Iftikhar Shah, Ikram ul Haq, Narmeen Nasir, Muhammad Tayyab Akhtar, Umar Farooq Gohar. Burgeoning therapeutic strategies to curb the contemporary surging viral infections. Microbial Pathogenesis 2023; 179: 106088 doi: 10.1016/j.micpath.2023.106088
|
| 14 |
Jelena Todoric, Laura Antonucci, Michael Karin. Targeting Inflammation in Cancer Prevention and Therapy. Cancer Prevention Research 2016; 9(12): 895 doi: 10.1158/1940-6207.CAPR-16-0209
|
| 15 |
M. H. Hyun, Y.‐S. Lee, J. H. Kim, J. H. Je, Y. J. Yoo, J. E. Yeon, K. S. Byun. Systematic review with meta‐analysis: the efficacy and safety of tenofovir to prevent mother‐to‐child transmission of hepatitis B virus. Alimentary Pharmacology & Therapeutics 2017; 45(12): 1493 doi: 10.1111/apt.14068
|
| 16 |
Shu-Rong Xiao, Gui-Dan Xu, Wu-Jun Wei, Bin Peng, Yi-Bin Deng. Antiviral effects of hepatitis B virus S gene-specific anti-gene locked nucleic acid in transgenic mice. World Journal of Clinical Cases 2018; 6(8): 183-191 doi: 10.12998/wjcc.v6.i8.183
Abstract(1171) |
Core Tip(969) |
Full Article(HTML)(3355)
|
Full Article (PDF)-2160K(417)
|
Full Article (Word)-10783K(363)
|
Audio-1152K(10)
|
Peer-Review Report-180K(213)
|
Answering Reviewers-290K(226)
|
Full Article (PDF)-2230K(46)
|
Full Article (XML)-71K(40)
|
Times Cited (1)
|
Total Visits (14120)
|
Open
|
| 17 |
Long Jianfei, Li Ling, Zhang Yu, Zhang Jiming, Wang Bin. Tooth loss associated with the use of tenofovir disoproxil fumarate. Journal of Clinical Pharmacy and Therapeutics 2020; 45(6): 1478 doi: 10.1111/jcpt.13219
|
| 18 |
Uma S. Singh, Varughese A. Mulamoottil, Chung K. Chu. 2′‐Fluoro‐6′‐methylene carbocyclic adenosine and its phosphoramidate prodrug: A novel anti‐HBV agent, active against drug‐resistant HBV mutants. Medicinal Research Reviews 2018; 38(3): 977 doi: 10.1002/med.21490
|
| 19 |
Feipeng Xu, Hua Zhang, Jiamei Chen, Junyi Zhan, Ping Liu, Wei Liu, Shenglan Qi, Yongping Mu. Recent progress on the application of compound formulas of traditional Chinese medicine in clinical trials and basic research in vivo for chronic liver disease. Journal of Ethnopharmacology 2024; 321: 117514 doi: 10.1016/j.jep.2023.117514
|
| 20 |
Nese Inan, Fehmi Tabak. Viral Hepatitis: Chronic Hepatitis B. 2018; : 71 doi: 10.1007/978-3-319-93449-5_7
|
| 21 |
Geanne da Silva Lobato, Ademilton Alves Farias, Alessandra Pereira da Silva, José Raul Rocha de Araújo Júnior. Drug treatment of chronic hepatitis b in Brazil: a review. Gastroenterology & Hepatology: Open Access 2021; 12(6): 182 doi: 10.15406/ghoa.2021.12.00483
|
| 22 |
Janitha M. Unagolla, Subarna Das, Riley Flanagan, Marin Oehler, Jyothi U. Menon. Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives. International Journal of Pharmaceutics 2024; 660: 124381 doi: 10.1016/j.ijpharm.2024.124381
|
| 23 |
Jiaqian Pan, Shuangmei Tong, Lei Kang, Jing Tang. New anti-hepatitis B virus drugs under development and evaluation. Current Opinion in Infectious Diseases 2016; 29(6): 632 doi: 10.1097/QCO.0000000000000318
|
| 24 |
Rocío González Grande, Inmaculada Santaella Leiva, Susana López Ortega, Miguel Jiménez Pérez. Present and future management of viral hepatitis. World Journal of Gastroenterology 2021; 27(47): 8081-8102 doi: 10.3748/wjg.v27.i47.8081
|
| 25 |
Pardis Mohammadi Pour, Sajad Fakhri, Sedigheh Asgary, Mohammad Hosein Farzaei, Javier Echeverría. The Signaling Pathways, and Therapeutic Targets of Antiviral Agents: Focusing on the Antiviral Approaches and Clinical Perspectives of Anthocyanins in the Management of Viral Diseases. Frontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.01207
|
| 26 |
Tai-Cheng Zhou, Feng-Wei Liu, Jing-Hua Fan, Si-Hang Zhang, Song-Qin Lv, Zhi-Yong Yu, Yan-Mei Zhang, Liang Zhang, Jia Wei. The association of the heterogeneity of HBV reverse transcriptase quasispecies with antiviral efficacy after treatment with nucleos(t)ide analogues for 10 years. Infection, Genetics and Evolution 2021; 89: 104706 doi: 10.1016/j.meegid.2021.104706
|
| 27 |
Yang Zhang, Yi-Tong Wang, Jian-Xing Luo, Xiao-Yu Hu, Fang Yang, Wu Lin, Xiao Liang, Bing-Jie Zhao, Song Zhang, Yuan-Yuan Chen. Effect of WSP, a Chinese Herbal Formula, on Th17/Treg Ratio and HBeAg Seroconversion in Telbivudine-Treated HBeAg-Positive Chronic Hepatitis B Patients with High Baseline ALT Levels (20–30 Times the ULN). Evidence-Based Complementary and Alternative Medicine 2019; 2019: 1 doi: 10.1155/2019/7260369
|
| 28 |
Wattana Leowattana, Tawithep Leowattana. Chronic hepatitis B: New potential therapeutic drugs target. World Journal of Virology 2022; 11(1): 57-72 doi: 10.5501/wjv.v11.i1.57
|
| 29 |
Dipali M. Dhoke, Shriniwas S. Basaiyye, Pramod B. Khedekar. Development and characterization of L-HSA conjugated PLGA nanoparticle for hepatocyte targeted delivery of antiviral drug. Journal of Drug Delivery Science and Technology 2018; 47: 77 doi: 10.1016/j.jddst.2018.06.006
|
| 30 |
Jinyu Zhang, Yi Zhang, Sushant Khanal, Dechao Cao, Juan Zhao, Xindi Dang, Lam Ngoc Thao Nguyen, Madison Schank, Xiao Y. Wu, Yong Jiang, Shunbin Ning, Ling Wang, Mohamed El Gazzar, Jonathan P. Moorman, Haitao Guo, Zhi Q. Yao. Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication. Journal of Medical Virology 2023; 95(7) doi: 10.1002/jmv.28952
|
| 31 |
Dmitry Kostyushev, Sergey Brezgin, Anastasiya Kostyusheva, Dmitry Zarifyan, Irina Goptar, Vladimir Chulanov. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus. Cellular and Molecular Life Sciences 2019; 76(9): 1779 doi: 10.1007/s00018-019-03021-8
|
| 32 |
Prakriti Sinha, Parul Sahu. Dynamics of Immune Activation in Viral Diseases. 2020; : 205 doi: 10.1007/978-981-15-1045-8_14
|
| 33 |
Blessing A Aderibigbe. Polymeric Therapeutic Delivery Systems for the Treatment of Infectious Diseases. Therapeutic Delivery 2017; 8(7): 557 doi: 10.4155/tde-2017-0008
|
| 34 |
Sonia Singh, Shiwangi Sharma, Himanshu Sharma. Naturally Occurring Herbs and their Bioactive Metabolites: Potential Targets and Signaling Pathways of Antiviral Agents. Endocrine, Metabolic & Immune Disorders - Drug Targets 2023; 23(12): 1505 doi: 10.2174/1871530323666230622122901
|
| 35 |
Qian Zhang, Da-Chuan Cai, Peng Hu, Hong Ren. Low-level viremia in nucleoside analog-treated chronic hepatitis B patients. Chinese Medical Journal 2021; 134(23): 2810 doi: 10.1097/CM9.0000000000001793
|
| 36 |
Feilin Ge, Yan Yang, Zhaofang Bai, Lanlan Si, Xuemei Wang, Jia Yu, Xiaohe Xiao, Yan Liu, Zhigang Ren. The role of Traditional Chinese medicine in anti-HBV: background, progress, and challenges. Chinese Medicine 2023; 18(1) doi: 10.1186/s13020-023-00861-2
|
| 37 |
Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis. Clinical and Molecular Hepatology 2022; 28(2): 254 doi: 10.3350/cmh.2021.0314
|
| 38 |
Eunju Kim, Hyun Woong Lee, Soon Sun Kim, Eileen Yoon, Eun Sun Jang, Jong‐In Chang, Young Youn Cho, Gi Hyeon Seo, Hyung Joon Kim. Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South Korea. Alimentary Pharmacology & Therapeutics 2023; 58(11-12): 1185 doi: 10.1111/apt.17716
|
| 39 |
Hong Kim, Seoung-Ae Lee, Bum-Joon Kim. X region mutations of hepatitis B virus related to clinical severity. World Journal of Gastroenterology 2016; 22(24): 5467-5478 doi: 10.3748/wjg.v22.i24.5467
|
| 40 |
Mohammad Enamul Hoque Kayesh, Yutaka Amako, Md Abul Hashem, Shuko Murakami, Shintaro Ogawa, Naoki Yamamoto, Tatsuro Hifumi, Noriaki Miyoshi, Masaya Sugiyama, Yasuhito Tanaka, Masashi Mizokami, Michinori Kohara, Kyoko Tsukiyama-Kohara. Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA. Virus Research 2020; 290: 198191 doi: 10.1016/j.virusres.2020.198191
|
| 41 |
Jia‐Horng Kao, Tarik Asselah, Xiao‐Guang Dou, Kamal Hamed. Telbivudine therapy for chronic hepatitis B: A journey to identify super‐responders and to optimize treatment using the roadmap model. Journal of Gastroenterology and Hepatology 2017; 32(1): 73 doi: 10.1111/jgh.13512
|
| 42 |
Pobitra Borah, Sangeeta Hazarika, Mohamed A. Morsy, Manoj Goyal, Ashna Chettri, Katharigatta N. Venugopala, Viresh Mohanlall, Pratap Chandra Acharya, Pran Kishore Deb, Raghu Prasad Mailavaram. Medicinal Chemistry of Chemotherapeutic Agents. 2023; : 319 doi: 10.1016/B978-0-323-90575-6.00001-6
|
| 43 |
Ganesh Selvaraj Duraisamy, Dattatry Bhosale, Ivana Lipenská, Ivana Huvarova, Daniel Růžek, Marc P. Windisch, Andrew D. Miller. Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going?. Viruses 2020; 12(9): 998 doi: 10.3390/v12090998
|
| 44 |
Weiqiang Gan, Jianguo Li, Chunlan Zhang, Xuefu Chen, Chaoshuang Lin, Zhiliang Gao. Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections. BMC Infectious Diseases 2020; 20(1) doi: 10.1186/s12879-020-05642-y
|
| 45 |
Ahmed Lasfar, Andrew Zloza, Karine A. Cohen-Solal. IFN-lambda therapy: current status and future perspectives. Drug Discovery Today 2016; 21(1): 167 doi: 10.1016/j.drudis.2015.10.021
|
| 46 |
K. Reyes-Gordillo, R. Shah, M.R. Lakshman, R.E. Flores-Beltrán, P. Muriel. Liver Pathophysiology. 2017; : 687 doi: 10.1016/B978-0-12-804274-8.00049-7
|
| 47 |
Sajad Fakhri, Zeinab Nouri, Seyed Zachariah Moradi, Esra Küpeli Akkol, Sana Piri, Eduardo Sobarzo-Sánchez, Mohammad Hosein Farzaei, Javier Echeverría. Targeting Multiple Signal Transduction Pathways of SARS-CoV-2: Approaches to COVID-19 Therapeutic Candidates. Molecules 2021; 26(10): 2917 doi: 10.3390/molecules26102917
|